Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
180 sources

Section 6 of 6

References

180 sources

  1. 4D Molecular Therapeutics 2026 company update (2026) (opens in a new tab)
  2. 4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026) (opens in a new tab)
  3. 4D Molecular Therapeutics 4FRONT-1 first patients announcement (2025) (opens in a new tab)
  4. 4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026) (opens in a new tab)
  5. 4D Molecular Therapeutics corporate presentation (2026) (opens in a new tab)
  6. 4D Molecular Therapeutics Form 10-K (2026) (opens in a new tab)
  7. 4D Molecular Therapeutics Form 10-Q (2026) (opens in a new tab)
  8. 4D Molecular Therapeutics Form 8-K PRISM 2-year data (2026) (opens in a new tab)
  9. 4D Molecular Therapeutics Form 8-K protocol amendment (2025) (opens in a new tab)
  10. 4D Molecular Therapeutics Otsuka license announcement (2025) (opens in a new tab)
  11. 4D Molecular Therapeutics Phase 3 acceleration announcement (2025) (opens in a new tab)
  12. 4D Molecular Therapeutics PRIME designation announcement (2023) (opens in a new tab)
  13. 4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023) (opens in a new tab)
  14. 4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023) (opens in a new tab)
  15. 4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024) (opens in a new tab)
  16. 4D Molecular Therapeutics PRISM injection-free subgroup analyses announcement (2024) (opens in a new tab)
  17. 4D Molecular Therapeutics PRISM long-term data announcement (2025) (opens in a new tab)
  18. 4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026) (opens in a new tab)
  19. 4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025) (opens in a new tab)
  20. 4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024) (opens in a new tab)
  21. 4D Molecular Therapeutics RMAT designation announcement (2023) (opens in a new tab)
  22. 4D Molecular Therapeutics second quarter 2026 results (2026) (opens in a new tab)
  23. 4D Molecular Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  24. 4D Molecular Therapeutics wet AMD development day announcement (2024) (opens in a new tab)
  25. Abu Al-Burak et al. (2026) (opens in a new tab)
  26. Almony et al. (2021) (opens in a new tab)
  27. Amoaku et al. (2015) (opens in a new tab)
  28. Anastasopoulos et al. (2006) (opens in a new tab)
  29. ARVO Annual Meeting (2023) (opens in a new tab)
  30. ARVO Annual Meeting (2025) (opens in a new tab)
  31. Asanad et al. (2025) (opens in a new tab)
  32. Awh (2025) (opens in a new tab)
  33. Awh (2026) (opens in a new tab)
  34. Baljoon et al. (2026) (opens in a new tab)
  35. Baumal et al. (2020) (opens in a new tab)
  36. Berkowitz and Patel (2021) (opens in a new tab)
  37. Bhisitkul et al. (2015) (opens in a new tab)
  38. Bloch et al. (2012) (opens in a new tab)
  39. Bowen et al. (2026) (opens in a new tab)
  40. Brown et al. (2000) (opens in a new tab)
  41. Brown et al. (2006) (opens in a new tab)
  42. Brown et al. (2016) (opens in a new tab)
  43. Brown et al. (2020) (opens in a new tab)
  44. Brown et al. (2024) (opens in a new tab)
  45. Brown et al. (2025) (opens in a new tab)
  46. Bryan et al. (2025) (opens in a new tab)
  47. Busbee et al. (2013) (opens in a new tab)
  48. Calton et al. (2024) (opens in a new tab)
  49. Campochiaro et al. (2025) (opens in a new tab)
  50. CATT Research Group (2011) (opens in a new tab)
  51. Centers for Medicare & Medicaid Services Quality ID 14 (2019) (opens in a new tab)
  52. Chakravarthy et al. (2010) (opens in a new tab)
  53. Chakravarthy et al. (2013) (opens in a new tab)
  54. Cheung et al. (2026) (opens in a new tab)
  55. Christakis et al. (2020) (opens in a new tab)
  56. Ciulla et al. (2020) (opens in a new tab)
  57. ClinicalTrials.gov NCT04704921 (opens in a new tab)
  58. ClinicalTrials.gov NCT05197270 (opens in a new tab)
  59. ClinicalTrials.gov NCT05407636 (opens in a new tab)
  60. ClinicalTrials.gov NCT06223958 (opens in a new tab)
  61. ClinicalTrials.gov NCT06668064 (opens in a new tab)
  62. ClinicalTrials.gov NCT06683742 (opens in a new tab)
  63. ClinicalTrials.gov NCT06856577 (opens in a new tab)
  64. ClinicalTrials.gov NCT06864988 (opens in a new tab)
  65. ClinicalTrials.gov NCT07064759 (opens in a new tab)
  66. CMS Medicare Part B payment limit file (2026) (opens in a new tab)
  67. CMS Medicare Part B Spending by Drug (2026) (opens in a new tab)
  68. CMS Medicare Quarterly Part B Spending by Drug (2026) (opens in a new tab)
  69. Comparison of Age-related Macular Degeneration Treatments Trials Research Group (2016) (opens in a new tab)
  70. DailyMed BEOVU prescribing information (2025) (opens in a new tab)
  71. DailyMed EYLEA HD label (2026) (opens in a new tab)
  72. DailyMed EYLEA prescribing information (2026) (opens in a new tab)
  73. DailyMed LUCENTIS prescribing information (2025) (opens in a new tab)
  74. DailyMed SUSVIMO label (2025) (opens in a new tab)
  75. DailyMed VABYSMO label (2026) (opens in a new tab)
  76. DailyMed VISUDYNE prescribing information (2025) (opens in a new tab)
  77. Dang et al. (2024) (opens in a new tab)
  78. Daniel et al. (2018) (opens in a new tab)
  79. Danzig (2024) (opens in a new tab)
  80. Dawson et al. (2014) (opens in a new tab)
  81. Desai et al. (2024) (opens in a new tab)
  82. Dickson and James (2023) (opens in a new tab)
  83. Dugel et al. (2020) (opens in a new tab)
  84. Dugel et al. (2021) (opens in a new tab)
  85. Eichenbaum (2024) (opens in a new tab)
  86. Eichenbaum et al. (2025) (opens in a new tab)
  87. EU CTIS 2025-521349-25-00 (opens in a new tab)
  88. EU CTIS 2025-521349-25-00 (opens in a new tab)
  89. Eye Diseases Prevalence Research Group (2004) (opens in a new tab)
  90. EyePoint LUGANO topline results announcement (2026) (opens in a new tab)
  91. FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016) (opens in a new tab)
  92. Finger et al. (2020) (opens in a new tab)
  93. Fleckenstein et al. (2021) (opens in a new tab)
  94. Franco et al. (2026) (opens in a new tab)
  95. Gale et al. (2023) (opens in a new tab)
  96. Gale et al. (2026) (opens in a new tab)
  97. GBD 2019 Blindness and Vision Impairment Collaborators (2021) (opens in a new tab)
  98. GBD 2021 Global AMD Collaborators (2025) (opens in a new tab)
  99. Gillies et al. (2020) (opens in a new tab)
  100. Gohil et al. (2015) (opens in a new tab)
  101. Grunwald et al. (2017) (opens in a new tab)
  102. Heier et al. (2012) (opens in a new tab)
  103. Heier et al. (2022) (opens in a new tab)
  104. Ho et al. (2020) (opens in a new tab)
  105. Hoffmann-La Roche TENAYA protocol (2019) (opens in a new tab)
  106. Holekamp et al. (2014) (opens in a new tab)
  107. Holekamp et al. (2022) (opens in a new tab)
  108. Holz et al. (2015) (opens in a new tab)
  109. Investing.com Morgan Stanley Global Healthcare Conference transcript (2026) (opens in a new tab)
  110. Jabbarpoor Bonyadi et al. (2019) (opens in a new tab)
  111. Javitt et al. (2003) (opens in a new tab)
  112. Johnson et al. (2019) (opens in a new tab)
  113. Kay et al. (2023) (opens in a new tab)
  114. Kertes et al. (2020) (opens in a new tab)
  115. Khanani (2024a) (opens in a new tab)
  116. Khanani (2024d) (opens in a new tab)
  117. Khanani et al. (2022) (opens in a new tab)
  118. Khanani et al. (2023) (opens in a new tab)
  119. Khanani et al. (2024b) (opens in a new tab)
  120. Khanani et al. (2024c) (opens in a new tab)
  121. Kim et al. (2026) (opens in a new tab)
  122. Kodiak Sciences DAYLIGHT statistical analysis plan (2023) (opens in a new tab)
  123. Koh et al. (2017) (opens in a new tab)
  124. Korobelnik et al. (2026) (opens in a new tab)
  125. Kuznik et al. (2025) (opens in a new tab)
  126. Lanzetta et al. (2024) (opens in a new tab)
  127. Leitch et al. (2024) (opens in a new tab)
  128. Li et al. (2020) (opens in a new tab)
  129. Maesa et al. (2022) (opens in a new tab)
  130. Malhotra et al. (2026) (opens in a new tab)
  131. Managed Healthcare Executive (2025) (opens in a new tab)
  132. Maturi (2024) (opens in a new tab)
  133. McGuinness et al. (2017) (opens in a new tab)
  134. Mitchell et al. (2018) (opens in a new tab)
  135. National Institute for Health and Care Excellence (2018) (opens in a new tab)
  136. Niazi et al. (2020) (opens in a new tab)
  137. Obeid et al. (2018) (opens in a new tab)
  138. Ocular Therapeutix SOL-1 topline results announcement (2026) (opens in a new tab)
  139. Okada et al. (2021) (opens in a new tab)
  140. Patel (2018) (opens in a new tab)
  141. Pieramici (2025) (opens in a new tab)
  142. Prenner et al. (2015) (opens in a new tab)
  143. Quesada et al. (2025) (opens in a new tab)
  144. Regillo et al. (2015) (opens in a new tab)
  145. Rein et al. (2022a) (opens in a new tab)
  146. Rein et al. (2022b) (opens in a new tab)
  147. Repka and Woodke (2025) (opens in a new tab)
  148. Rofagha et al. (2013) (opens in a new tab)
  149. Rosenfeld et al. (2006) (opens in a new tab)
  150. Rosenfeld et al. (2018) (opens in a new tab)
  151. Rudnicka et al. (2015) (opens in a new tab)
  152. Sadda et al. (2020) (opens in a new tab)
  153. Schmidt-Erfurth et al. (2014) (opens in a new tab)
  154. Senra et al. (2017) (opens in a new tab)
  155. Silva (2024) (opens in a new tab)
  156. Singh and Sørensen (2012) (opens in a new tab)
  157. Sood et al. (2022) (opens in a new tab)
  158. Spaide et al. (2020) (opens in a new tab)
  159. Spark Therapeutics Form 10-K (2019) (opens in a new tab)
  160. Spark Therapeutics Form 8-K (2018) (opens in a new tab)
  161. Spooner et al. (2026) (opens in a new tab)
  162. Stein et al. (2013) (opens in a new tab)
  163. Teo et al. (2026) (opens in a new tab)
  164. Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group (1999) (opens in a new tab)
  165. Tsang et al. (2024) (opens in a new tab)
  166. Van Vu et al. (2024) (opens in a new tab)
  167. Varano et al. (2015) (opens in a new tab)
  168. Vemulakonda et al. (2025) (opens in a new tab)
  169. Viola et al. (2024) (opens in a new tab)
  170. Vision Loss Expert Group of the Global Burden of Disease Study (2024) (opens in a new tab)
  171. Vu et al. (2021) (opens in a new tab)
  172. Vu et al. (2023) (opens in a new tab)
  173. WHO Collaborating Centre for Drug Statistics Methodology ATC index (2026) (opens in a new tab)
  174. Willmington et al. (2025) (opens in a new tab)
  175. Windsor et al. (2018) (opens in a new tab)
  176. Wong et al. (2008) (opens in a new tab)
  177. Wong et al. (2014) (opens in a new tab)
  178. Wykoff et al. (2018) (opens in a new tab)
  179. Xin et al. (2018) (opens in a new tab)
  180. Zhang et al. (2023) (opens in a new tab)